A policy change allowing approval of some new drugs based on one adequate and well-controlled study could accelerate ...
DHL Group—capitalizing off the momentum garnered from the LAX cold storage project —is expanding its dedicated airfreight cold chain network, aimed at strengthening global logistics for ...
Turning to market access, Eli Lilly has entered a $100 million licensing agreement with CSL Limited for clazakizumab. While CSL maintains the rights for kidney-related cardiovascular trials, Lilly ...
In the first part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, explains how third round of CMS drug selections brings physician-administered medicines under ...
This eBook highlights Werner’s premium and expedited shipping solutions designed specifically to address the high-stakes requirements of the $1.6 trillion global pharmaceutical industry. It details ...
In today’s Pharma Pulse, HHS Secretary RFK Jr. centralizes department operations under CMS leadership, while a new telehealth model shows a 66% reduction in repeat ER visits for older adults.
The online pharmacy is collaborating with a digital health provider to combine direct-to-patient GLP-1 dispensing with virtual clinical support, highlighting evolving supply chain and regulatory ...
A 2026 industry survey finds mounting pressure from PBMs, federal pricing reforms, and compliance scrutiny, as manufacturers ...
In the final part of his Pharma Commerce video interview, Dan Chancellor, Norstella’s vice president of thought leadership, shares that companies facing the largest revenue gaps from looming patent ...
Pharma’s $372B M&A surge fights a $300B patent cliff, with firms relying on early-stage assets and Chinese innovation to fill gaps by 2030.
In the second part of his Pharma Commerce video interview, Dan Chancellor, Norstella’s vice president of thought leadership, suggests that 2026 pharma M&A may fall short of last year’s $220 billion ...
In today’s Pharma Pulse, the Senate tackles the regulatory red tape driving physician burnout, while Edwards Lifesciences ends its anti-copycat policy to settle European Commission antitrust concerns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results